Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.77 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9534906 | 0.92 | GRIN2B (0.64) | GRIN2BGRIN1CCR3GRIN2ADRD4 | |
| SCHEMBL1388535 | 0.87 | GRIN2B (1.00) | GRIN2BGRIN1THRBCCR3GRIN2A | |
| SCHEMBL7073777 | 0.82 | GRIN2B (0.52) | GRIN2BGRIN1GRIN2ADRD4GRIN2C | |
| SCHEMBL5237195 | 0.81 | GRIN1 (0.84) | GRIN2BGRIN1THRBCCR3GRIN2A | |
| SCHEMBL7241045 | 0.81 | GRIN1 (0.65) | GRIN2BGRIN1THRBCCR3HRH3 | |
| SCHEMBL8313723 | 0.79 | GRIN1 (1.00) | GRIN2BGRIN1THRBGRIN2AGRIN2C | |
| SCHEMBL7099609 | 0.79 | GRIN2B (0.65) | GRIN2BGRIN1THRBCCR3GRIN2A | |
| SCHEMBL5239708 | 0.78 | GRIN1 (0.71) | GRIN2BGRIN1THRBDRD4 | |
| SCHEMBL7972912 | 0.78 | GRIN2B (0.83) | GRIN2BGRIN1CCR3GRIN2ADRD4 | |
| SCHEMBL7016716 | 0.78 | GRIN2B (0.71) | GRIN2BGRIN1THRBCCR3GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2003-01-23 | — | — | US | claimed |
| US-6476041-B1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-11-05 | — | — | US | claimed |
| EP-1235798-A4 | 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2003-01-23 | — | — | US | disclosed |
| US-6476041-B1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-11-05 | — | — | US | disclosed |
| EP-1235798-A1 | 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001032615-A1 | 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | GRIN1, GRIN2A, GRIN2B | GRIN2B 3/4885GRIN1 1/4885THRB 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.